Cytek Biosciences Inc (CTKB)
Return on total capital
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | — | -13,638 | 3,833 | 9,157 | 14,763 |
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 395,737 | 393,064 | 425,295 | 406,458 | -16,028 |
| Return on total capital | 0.00% | -3.47% | 0.90% | 2.25% | — |
December 31, 2024 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $395,737K)
= 0.00%
Cytek Biosciences Inc's return on total capital has shown fluctuation over the years. In 2021, the return on total capital was 2.25%, indicating that for every dollar of total capital employed, the company generated a return of 2.25 cents. However, in the following years, there was a decline with returns of 0.90% in 2022, -3.47% in 2023, and 0.00% in 2024, suggesting a decreasing trend in the company's ability to generate profits from its total capital. The negative return in 2023 raises concerns as it indicates that the company may not have efficiently utilized its capital to generate profits. Further analysis is required to understand the factors contributing to these fluctuations and to identify potential strategies for improving the return on total capital.
Peer comparison
Dec 31, 2024